NO952781L - Potensiering av temozolomid i humane tumorceller - Google Patents

Potensiering av temozolomid i humane tumorceller

Info

Publication number
NO952781L
NO952781L NO952781A NO952781A NO952781L NO 952781 L NO952781 L NO 952781L NO 952781 A NO952781 A NO 952781A NO 952781 A NO952781 A NO 952781A NO 952781 L NO952781 L NO 952781L
Authority
NO
Norway
Prior art keywords
temozolomide
potentialization
tumor cells
human tumor
atase
Prior art date
Application number
NO952781A
Other languages
English (en)
Norwegian (no)
Other versions
NO952781D0 (no
Inventor
John Colin Baer
Azadeh Alison Freeman
Edward Stuart Newlands
Amanda Jean Watson
Joseph Anthony Rafferty
Geoffrey Paul Margison
Original Assignee
Cancer Res Campaign Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech filed Critical Cancer Res Campaign Tech
Publication of NO952781D0 publication Critical patent/NO952781D0/no
Publication of NO952781L publication Critical patent/NO952781L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO952781A 1993-01-14 1995-07-13 Potensiering av temozolomid i humane tumorceller NO952781L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US475493A 1993-01-14 1993-01-14
PCT/GB1994/000065 WO1994015615A1 (en) 1993-01-14 1994-01-13 Potentiation of temozolomide in human tumour cells

Publications (2)

Publication Number Publication Date
NO952781D0 NO952781D0 (no) 1995-07-13
NO952781L true NO952781L (no) 1995-09-13

Family

ID=21712364

Family Applications (1)

Application Number Title Priority Date Filing Date
NO952781A NO952781L (no) 1993-01-14 1995-07-13 Potensiering av temozolomid i humane tumorceller

Country Status (20)

Country Link
EP (2) EP0679086A1 (ru)
JP (1) JPH08505615A (ru)
KR (1) KR100352046B1 (ru)
CN (1) CN1277541C (ru)
AU (1) AU5838494A (ru)
CA (1) CA2153775C (ru)
CZ (1) CZ286550B6 (ru)
FI (1) FI953423A (ru)
HU (1) HUT72665A (ru)
IL (1) IL108328A (ru)
MX (1) MX9400434A (ru)
MY (1) MY116474A (ru)
NO (1) NO952781L (ru)
PL (1) PL175842B1 (ru)
RU (1) RU2148401C1 (ru)
SK (1) SK282452B6 (ru)
TW (1) TW414710B (ru)
UA (1) UA29466C2 (ru)
WO (1) WO1994015615A1 (ru)
ZA (1) ZA94248B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731304A (en) * 1982-08-23 1998-03-24 Cancer Research Campaign Technology Potentiation of temozolomide in human tumour cells
US5942247A (en) * 1996-07-31 1999-08-24 Schering Corporation Method for treating pediatric high grade astrocytoma including brain stem glioma
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
AU2021700A (en) * 1998-12-07 2000-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
AR038535A1 (es) * 2002-02-22 2005-01-19 Schering Corp Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
AU2003237347B2 (en) * 2002-05-31 2009-07-23 Transmolecular Inc. Treatment of cell proliferative disorders with chlorotoxin
CN100431605C (zh) * 2005-02-03 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100402091C (zh) * 2005-02-03 2008-07-16 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100350974C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 一种抗癌药物组合物
CN100350975C (zh) * 2005-02-03 2007-11-28 山东蓝金生物工程有限公司 抗癌药物组合物
GB0502573D0 (en) * 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
JP2011520914A (ja) 2008-05-15 2011-07-21 トランスモレキュラー， インコーポレイテッド 転移腫瘍の処置
CN102844044B (zh) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 氯毒素多肽和结合物及其应用
JP2013532126A (ja) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
CN103169664B (zh) * 2011-12-25 2015-04-22 复旦大学 一种rgd肽修饰的双层载药纳米粒及其制备方法
RU2015126651A (ru) 2012-12-10 2017-01-16 Фред Хатчинсон Кэнсер Рисёрч Сентер Способы скрининга
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof

Also Published As

Publication number Publication date
IL108328A (en) 2010-05-31
MY116474A (en) 2004-02-28
PL309915A1 (en) 1995-11-13
JPH08505615A (ja) 1996-06-18
CZ179795A3 (en) 1996-04-17
CA2153775C (en) 2000-11-14
TW414710B (en) 2000-12-11
WO1994015615A1 (en) 1994-07-21
EP0679086A1 (en) 1995-11-02
IL108328A0 (en) 1994-04-12
CN1117711A (zh) 1996-02-28
EP0922458A1 (en) 1999-06-16
KR960700063A (ko) 1996-01-19
FI953423A (fi) 1995-08-23
ZA94248B (en) 1994-07-13
SK89295A3 (en) 1996-06-05
FI953423A0 (fi) 1995-07-13
CN1277541C (zh) 2006-10-04
KR100352046B1 (ko) 2003-09-03
UA29466C2 (ru) 2000-11-15
CA2153775A1 (en) 1994-07-21
MX9400434A (es) 1994-07-29
SK282452B6 (sk) 2002-02-05
HUT72665A (en) 1996-05-28
RU2148401C1 (ru) 2000-05-10
AU5838494A (en) 1994-08-15
PL175842B1 (pl) 1999-02-26
CZ286550B6 (cs) 2000-05-17
HU9502117D0 (en) 1995-09-28
NO952781D0 (no) 1995-07-13

Similar Documents

Publication Publication Date Title
NO952781L (no) Potensiering av temozolomid i humane tumorceller
EA200001245A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ ПИРРОЛО [2,3d] ПИРИМИДИНОВ И ИХ ПРИМЕНЕНИЕ
DE69427862T2 (de) K-252a derivate, die neurotrophin-induzierte aktivität erhöhen
NO932954D0 (no) 2,4-diaminokinazolin-derivater for aa oppnaa oeket antitumoraktivitet
TR200200160T2 (tr) Antiinflamatuar ajanlar olarak imidazoller ve triazoller
PT907652E (pt) Compostos e processos imunossupressores
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
DK0556310T3 (da) Quinazolinderivater til forhøjelse af antitumoraktivitet
ATE240334T1 (de) Pyrrolobenzodiazepine
ES2174863T3 (es) Compuestos de pirimidina y su uso como compuestos farmaceuticos.
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
DE60319406D1 (de) Meso-substituierte porphyrine
BR0108715A (pt) Compostos de 3,4-diidro-1h-pirimido[4,5-d]-pirimidin-2-ona 1,5-dissubstituìdos e seu uso no tratamento de doenças mediadas pela cinase csbp/p38
MX9308013A (es) 4-fenil-piridonas y 4-fenil-2-fenil-2-alcoxipiridinas sustituidas, procedimiento para su preparacion y medicamentos que los contienen.
HRP20050387A2 (en) DERIVATIVES OF [6,7-DIHYDRO-5H-IMIDAZO[1,2-α] IMIDAZOLE-3-SULFONYLAMINO]-PROPIONAMIDE
DK0869965T3 (da) Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
MXPA03003923A (es) Compuestos de n-([1,2,4]triazoloazinil)tiofensulfonamida como herbicidas.
PT983272E (pt) Nova classe de compostos fotoactivos derivados de benzoporfirina
DE58908290D1 (de) Disubstituierte Pyridine.
DE69126469D1 (de) Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten
DE60008400D1 (de) Triazolopyrimidinderivate
ES2218814T3 (es) Uso de queleritrina y radiacion para el tratamiento de tumores.
NL180893C (nl) Stelsel voor het opwekken van een elektronenbundel voor toepassing bij de fabrikage van geintegreerde ketens.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application